Journal
FRONTIERS IN MICROBIOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmicb.2020.01105
Keywords
Remdesivir (GS-5734); antivirals; EV71; vRNA; cRNA; enterovirus
Categories
Funding
- National Key Research and Development Program of China [2016YFC1200400]
- National Natural Science Foundation of China [81871697, 31600131, 81702003]
- Open Fund of the State Key Laboratory of Pathogenic Microbial Biosafety [SKLPBS1834]
- Key Research and Development Program of Shaanxi Province [2020SF-227, 2018JSTS03]
Ask authors/readers for more resources
Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy. Thus, a therapeutic agent for the enterovirus-related disease is urgently needed. Remdesivir (GS-5734) is a novel monophosphoramidate adenosine analog prodrug that exhibits potent antiviral activity against diverse RNA virus families, including positive-senseCoronaviridaeandFlaviviridaeand negative-senseFiloviridae,Paramyxoviridae, andPneumoviridae. Currently, remdesivir is under phase 3 clinical development for disease COVID-19 treatment. Here, we found that remdesivir impeded both EV71 viral RNA (vRNA) and complementary (cRNA) synthesis, indicating that EV71 replication is inhibited by the triphosphate (TP) form of remdesivir. Moreover, remdesivir showed potent antiviral activity against diverse enteroviruses. These data extend the remdesivir antiviral activity to enteroviruses and indicate that remdesivir is a promising antiviral treatment for EV71 and other enterovirus infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available